Envisagenics

Envisagenics is a spinout of the world-renowned Cold Spring Harbor Laboratory (CSHL) from the laboratory of Dr. Adrian R. Krainer, a leading expert in the field of splicing. The Krainer laboratory was the first to perform in-vitro splicing studies, identify the regulatory proteins of alternative splicing, and discover their involvement in cancer and genetic diseases, all of which led to proving the efficacy of RNA therapeutics to cure disease with the FDA approval of Spinraza for treating Spinal Muscular Atrophy.

Under the leadership of Dr. Maria Luisa Pineda, Envisagenics Co-founder and CEO, and Dr. Martin Akerman, Co-founder and CTO, the company has continued to further develop its machine learning drug discovery platform, and has validated its capabilities through publications, proof-of-concept studies with academia and biopharma partners, and acquisition of private and non-dilutive funding.